Advertisement

Click here for more guidelines.
2012 ACCF/ AATS/ SCAI/ STS Expert Consensus Document on Transcatheter Aortic Valve Replacement
ACCF/ SCAI/ STS/ AATS/ AHA/ ASNC/ HFSA/ SCCT 2012 Appropriate Use Criteria for Coronary Revascularization Focused Update
2012 ACCF/ AHA/ ACR/ SCAI/ SIR/ STS/ SVM/ SVN Key Data Elements and Definitions for Peripheral Atherosclerotic Vascular Disease

 
About JACC CME
Policy on Privacy and Confidentiality
Disclosures
Important Information
 

JACC Imaging Homepage JACC Interventions Homepage
Still not a subscriber to JACC Imaging or JACC Interventions?
Click here
to sign up now!

Submit Manuscripts
Author Information
Subscribe/Renew
Order Reprints
Email Alerts
Feedback
RSS Feed
CME
 
 

Cardiosmart
Cardiosource
CVN
Imaging Library
JACC Imaging
JACC Interventions
 
 

About the Journal
Editorial Board & Staff
 
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2009; 54:505-512, doi:10.1016/j.jacc.2009.03.066
© 2009 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow View Cardiosource Talk Back
Right arrow View Related Cardiosource Journal Scan
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Edwards, N. C.
Right arrow Articles by Townend, J. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Edwards, N. C.
Right arrow Articles by Townend, J. N.
Related Collections
Right arrowRelated Articles

Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease

A Randomized Controlled Trial

Nicola C. Edwards, BMBS*, Richard P. Steeds, MD*, Paul M. Stewart, PhD{dagger}, Charles J. Ferro, MD{ddagger} and Jonathan N. Townend, MD*,*

* Department of Cardiology, University Hospital Birmingham and University of Birmingham, Birmingham, United Kingdom
{dagger} Department of Medicine, University Hospital Birmingham and University of Birmingham, Birmingham, United Kingdom
{ddagger} Department of Nephrology, University Hospital Birmingham and University of Birmingham, Birmingham, United Kingdom


Figure 1
View larger version (12K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1 Change in LV Mass and LV Mass Index in Patients Treated With Spironolactone and Placebo

Data are mean ± SEM. {dagger}{dagger}p < 0.01 treatment by time interaction, repeated measures analysis of variance. LV = left ventricular.

 

Figure 2
View larger version (18K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 2 Changes in PWV, Aug Ix 75, and Aortic Distensibility

(A) Pulse-wave velocity (PWV), (B) augmentation index corrected for heart rate of 75 beats/min (Aug Ix 75), and (C) aortic distensibility on cardiovascular magnetic resonance in patients treated with spironolactone (Spiro) and placebo. Data are mean ± SEM. {dagger}p < 0.05; {dagger}{dagger}p < 0.01 treatment by time interaction, repeated measures analysis of variance.

 

Figure 3
View larger version (25K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 3 Changes in LV Mass Index

Shown are changes in left ventricular (LV) mass index associated with (A) quartiles of central systolic blood pressure reduction and (B) quartiles of ambulatory systolic blood pressure (SBP) reduction in patients randomized to spironolactone. Data are mean ± SD. {dagger}{dagger}p < 0.01 trend between quartiles.

 
 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement